|  Sign up!  

scientia

Return to Course Listing

 

 

CME: Advanced Non-Small Cell Lung Cancer (NSCLC): Therapeutic Updates, Best Practices, and Barriers to Care

 


Program Description / Statement of Need:

In this online CME self-learning program:

Lung cancer is the leading cause of cancer-related death in the United States with nearly 221,000 new cases diagnosed and 156,390 deaths annually. While surgery in eligible candidates and early detection provide the best chances for cure, there are many patients who must be treated by alternative modalities, including those with advanced disease.  Increasingly now, research is uncovering the role of biomarkers and genetic mutations in aiding not only the prognosis of NSCLC, but also its management.  They have given rise to targeted therapies that mechanistically alter cellular signaling pathways in a manner that suppresses angiogenesis and oncologic disease progression.

 

On the practical side, the literature also suggests that: there are or may be emerging or existing patterns of disparities in healthcare, treatment, and outcomes of patients with NSCLC on the basis of race, disability, and insurance coverage.  In particular, race- and ethnicity-based discrimination within the healthcare environment are associated with disparities in care; and that such discrimination is associated with both worse chronic health condition control and a higher incidence catastrophic health events.

 

This program has been designed to bring healthcare professionals’ knowledge of the rationale behind treatment of NSCLC up to date and to enhance their competence in caring for patients with NSCLC.  This program also attempts to examine the role of disparities in care of patients with NSCLC and strategies to minimize or alleviate those disparities.

 

Agenda

 

Introduction, Disclosures

Epidemiology and pathophysiology of and risk factors for NSCLS

•          Who is most affected? – Demographics

•          Risk factors: smoking, environmental, medical, and genetic

Symptomology and diagnosis of NSCLC

•          Physical symptoms, early screening, and diagnosis

•          Emerging role of biomarkers

•          Roles of imaging and biopsy

•          Clinical practice guidance – from the NCCN on down

•          Patient cases

Treatment in patients with NSCLC 

•          Distinction by biomarkers, performance assessment, stages, and smoking history

•          Roles of: performance status assessment, surgery, biological and targeted immunotherapy, adjuvant chemotherapy and

                          radiation therapy

•          Metastatic disease

•          Palliative care: who, when, and how to broach?

•          Barriers to care

•          Patient cases

Summary, conclusions, and best practice recap


 

Target Audience:

 

Healthcare professionals specializing in: interventional radiology; nuclear medicine; oncology; palliative care; pathology; pulmonology; or those who otherwise commonly care for patients with NSCLC.



Program Objectives:

By the end of the session the participant will be able to:

    • Describe the role and value of biopsy, molecular testing, and biomarkers in determining the natural course of disease and associated therapy, including the selection of targeted treatment modalities and signaling pathway inhibitors against NSCLC.
    • Describe the effect of altering signaling pathways on the cell life cycle, prognosis, clinical outcomes, and likelihood of response to different therapies in NSCLC.
    • Apply existing research and recommendations to practice in the management of NSCLC.
    • Distinguish between the most appropriate treatment approaches to NSCLC based on the following: genetic mutation and biomarker status according to the most up-to-date advances in research and by cancer stage according to the most up-to-date and best practice for NSCLC.
    • Taking into account disease stage, mutation status, prior treatment, past medical history, and prognostic indicators, evaluate a treatment plan for a specific patient based on degree of NSCLC to optimize safety, efficacy, tolerability, and barriers to care, suggesting modifications for improvement.


    Accreditation:

    ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.



    Release Date: February 18, 2013
    Expiration Date: February 18, 2015

    Faculty: Delila Katz PharmD, BCOP


    Faculty Disclosure and Resolution of COI:

     As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

     

    Faculty Disclosure: Delila Katz, PharmD has no relevent financial discloses..

     

    Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Bayer, Edwards Lifesciences, Eisai, Daiichi-Sankyo, Lilly, Merck, Pfizer, Sanofi Aventis, Wolf-Torey Medical.

     

    Commercial Support Disclosure: This program is supported by an educational grant from Boehringer Ingelheim

     

    Viewing Instructions

     

    PC

    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    MAC
    Mac OS 10.2.8
    Safari
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh

     

    *Required to view Printable PDF Version

     

    Privacy Policy

     

    Instructions:


    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.



    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


    Download the Presentation (optional)


     

    View the online program

     

    Perform Post-Test


    Complete the Symposium Evaluation and Request CE Certificate



Commercial Support Disclosure: This program is supported by an educational grant from Boehringer Ingelheim

 


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.